Analysis suggests that the research and development of DMTs and non-motor therapies will diversify Parkinson's treatment ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has ...

Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...

A team of researchers from the University of Barcelona and the Bellvitge Biomedical Research Institute (IDIBELL) has identified a potential biomarker of Parkinson's disease progression.

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

According to the new study, patients with a slow progression ... In the future, the discovery may be used in treatment for Parkinson's ...

Researchers at Tel Aviv University (TAU) discovered a new factor in the pathology of Parkinson's ... The study was backed by ...

GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...

There is a new and promising form of treatment for those suffering from Parkinson’s Disease and it could be as simple as ...

Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study  examined the ...

Alzheimer's Drug May Slow Down Cognitive Decline in ... to automaticaly quanitfy motor systems in early-stage Parkinson's ... New Visual Technique Could Advance Early Detection of ...